Citadel Advisors
SIOX

Citadel Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Citadel Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,300
Closed -$27K – 15033
2021
Q4 		$27K Buy
21,300
+6,100
+40% +$10.8K ﹤0.01% 13513
2021
Q3 		$33K Sell
15,200
-14,600
-49% -$31.7K ﹤0.01% 13546
2021
Q2 		$81K Buy
29,800
+4,100
+16% +$10.2K ﹤0.01% 13074
2021
Q1 		$67K Sell
25,700
-97,500
-79% -$276K ﹤0.01% 12766
2020
Q4 		$343K Sell
123,200
-7,300
-6% -$21.3K ﹤0.01% 8839
2020
Q3 		$603K Buy
+130,500
New +$431K ﹤0.01% 6952
2020
Q1 		– Sell
-10,900
Closed -$56K – 10397
2019
Q4 		$56K Buy
+10,900
New +$60.5K ﹤0.01% 8726
2019
Q2 		– Sell
-9,450
Closed -$101K – 10079
2019
Q1 		$101K Buy
9,450
+4,137
+78% +$41.2K ﹤0.01% 8556
2018
Q4 		$42K Sell
5,313
-2,850
-35% -$41.1K ﹤0.01% 8535
2018
Q3 		$158K Sell
8,163
-3,412
-29% -$62.1K ﹤0.01% 8361
2018
Q2 		$209K Buy
11,575
+8,987
+347% +$133K ﹤0.01% 7819
2018
Q1 		$28K Sell
2,588
-2,925
-53% -$47K ﹤0.01% 8064
2017
Q4 		$232K Sell
5,513
-3,337
-38% -$150K ﹤0.01% 6884
2017
Q3 		$487K Buy
8,850
+2,325
+36% +$392K ﹤0.01% 5374
2017
Q2 		$1.21M Buy
6,525
+2,525
+63% +$443K ﹤0.01% 3821
2017
Q1 		$478K Buy
4,000
+2,100
+111% +$220K ﹤0.01% 5104
2016
Q4 		$189K Buy
+1,900
New +$200K ﹤0.01% 6347
2016
Q1 		– Sell
-538
Closed -$78K – 8290
2015
Q4 		$78K Sell
538
-1,112
-67% -$145K ﹤0.01% 6938
2015
Q3 		$171K Buy
+1,650
New +$193K ﹤0.01% 6346

Other funds holding SIOX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Citadel Advisors's SIOX Position: Q1 2023 in Review

Citadel Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 15,202 shares — an estimated $6.61K sold.

Citadel Advisors first reported a position in SIOX in Q2 2015 and held it in 28 quarters. The position peaked at $9.28M in Q1 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

  • Citadel Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 15,202 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $6.61K.
  • Citadel Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 28 quarters.
  • Citadel Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $9.28M in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.